FDA Pulls Boxed Warnings on Asthma Risks on Some Inhalers
By Michael Mezher -
Published 21 December 2017
The US Food and Drug Administration (FDA) on Wednesday said it approved new labeling for inhalers that combine long-acting beta agonists (LABAs) and inhaled corticosteroids (ICS) after reviewing safety data from four clinical trials that showed that the combination of those drugs do not result in a significant increase in asthma-related side effects or deaths.
Categories: News, US, FDA, Combination products, Drugs, Labeling
Tags: long-acting beta agonists, LABA, inhaled corticosteroids, ICS